Table 2.
Subgroup analysis
| Subgroup | No of studies | Heterogeneity | Pooled HR (95% CI) | P values | |
| I2 (95% CI) | P values | ||||
| Total | 12 | 38.2% (0% to 68.7%) | 0.086 | 1.42 (1.30 to 1.55) | <0.001 |
| Ethnic subtotal | |||||
| Caucasian | 2 | 71.6% (0% to 93.6%) | 0.06 | 1.48 (1.21 to 1.81) | <0.001 |
| Asian | 10 | 36.1% (0% to 69.5%) | 0.12 | 1.40 (1.27 to 1.55) | <0.001 |
| Disease subtotal | |||||
| Digestive system | 7 | 34.8% (0% to 72.4%) | 0.163 | 1.36 (1.22 to 1.51) | <0.001 |
| Respiratory system | 1 | NA | NA | 1.28 (1.02 to 1.61) | 0.036 |
| Blood system | 2 | 0 | 0.713 | 2.38 (1.56 to 3.63) | <0.001 |
| Glioma | 1 | NA | NA | 1.61 (1.19 to 2.18) | 0.002 |
| Osteosarcoma | 1 | NA | NA | 1.61 (1.19 to 2.18) | <0.001 |
| Detected method subtotal | |||||
| qRT-PCR | 11 | 29.0% (0% to 65.0%) | 0.169 | 1.40 (1.28 to 1.53) | <0.001 |
| ISH | 1 | NA | NA | 2.59 (1.39 to 4.81) | 0.003 |
| Detected sample subtotal | |||||
| Tissue | 10 | 46.2% (0% to 74.1%) | 0.053 | 1.45 (1.31 to 1.61) | <0.001 |
| Serum | 2 | 0 | 0.662 | 1.32 (1.10 to 1.57) | 0.002 |
| Detection of miR-17 subtotal | |||||
| miR-17 | 8 | 60.1% (13.2% to 81.7%) | 0.057 | 1.29 (1.11 to 1.49) | <0.001 |
| miR-17–5p | 4 | 7.5% (0% to 43.4%) | 0.372 | 1.50 (1.34 to 1.67) | 0.001 |
ISH, in situ hybridisation; miR-17, microRNA-17; miR-17-5p, microRNA-17-5p; NA, not available; qRT-PCR, quantitative real-time PCR.